JP2016513730A5 - - Google Patents

Download PDF

Info

Publication number
JP2016513730A5
JP2016513730A5 JP2016502750A JP2016502750A JP2016513730A5 JP 2016513730 A5 JP2016513730 A5 JP 2016513730A5 JP 2016502750 A JP2016502750 A JP 2016502750A JP 2016502750 A JP2016502750 A JP 2016502750A JP 2016513730 A5 JP2016513730 A5 JP 2016513730A5
Authority
JP
Japan
Prior art keywords
alkyl
haloalkyl
pharmaceutically acceptable
acceptable salt
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016502750A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016513730A (ja
JP6442475B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/028274 external-priority patent/WO2014144037A1/en
Publication of JP2016513730A publication Critical patent/JP2016513730A/ja
Publication of JP2016513730A5 publication Critical patent/JP2016513730A5/ja
Application granted granted Critical
Publication of JP6442475B2 publication Critical patent/JP6442475B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016502750A 2013-03-15 2014-03-14 Ｌｘｒ調節因子 Expired - Fee Related JP6442475B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361786974P 2013-03-15 2013-03-15
US61/786,974 2013-03-15
PCT/US2014/028274 WO2014144037A1 (en) 2013-03-15 2014-03-14 Lxr modulators

Publications (3)

Publication Number Publication Date
JP2016513730A JP2016513730A (ja) 2016-05-16
JP2016513730A5 true JP2016513730A5 (enExample) 2017-04-20
JP6442475B2 JP6442475B2 (ja) 2018-12-19

Family

ID=51537598

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016502750A Expired - Fee Related JP6442475B2 (ja) 2013-03-15 2014-03-14 Ｌｘｒ調節因子

Country Status (5)

Country Link
US (1) US9834542B2 (enExample)
EP (1) EP2968275B1 (enExample)
JP (1) JP6442475B2 (enExample)
CN (1) CN105209039B (enExample)
WO (1) WO2014144037A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2694001T3 (es) 2013-03-15 2018-12-17 Bristol-Myers Squibb Company Moduladores de LXR
US10669296B2 (en) 2014-01-10 2020-06-02 Rgenix, Inc. LXR agonists and uses thereof
CN104817525B (zh) * 2015-04-13 2017-11-17 江苏大学 含氟2,3‑二氢苯并呋喃‑3‑醇类化合物及制备方法
CA3010883A1 (en) 2016-01-11 2017-07-20 The Rockefeller University Methods for the treatment of myeloid derived suppressor cells related disorders
AU2018373028A1 (en) 2017-11-21 2020-04-30 Inspirna, Inc. Polymorphs and uses thereof
CN109867645B (zh) * 2017-12-05 2021-09-14 中国医学科学院药物研究所 一种2,2-二氟-2,3-二氢取代苯并呋喃类化合物的合成方法
TWI748194B (zh) * 2018-06-28 2021-12-01 德商菲尼克斯 Ｆｘｒ有限責任公司 含有雙環核心部分之新穎lxr調節劑
WO2020169069A1 (en) * 2019-02-21 2020-08-27 Nanjing Ruijie Pharma Co., Ltd. Novel compounds and their uses as thyroid hormone receptor agonists
CN110330493B (zh) * 2019-08-23 2020-07-24 广州麓鹏制药有限公司 Pim激酶抑制剂、其制备方法、应用、药物及药物组合
EP4073025B1 (en) 2019-12-13 2024-03-27 Inspirna, Inc. Metal salts and uses thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
WO1984002131A1 (fr) 1982-11-22 1984-06-07 Sandoz Ag Produits analogues de mevalolactone et leurs derives, leurs procedes de production, compositions pharmaceutiques les contenant ainsi que leur utilisation en tant que produits pharmaceutiques
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
ES2042520T3 (es) 1986-06-10 1993-12-16 Chiesi Farma Spa Composiciones farmaceuticas que contienen el ester metilico de levodopa, preparacion y aplicaciones terapeuticas del mismo.
US5138069A (en) 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
US5506219A (en) 1988-08-29 1996-04-09 E. R. Squibb & Sons, Inc. Pyridine anchors for HMG-CoA reductase inhibitors
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5177080A (en) 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
US5859035A (en) 1996-04-03 1999-01-12 Merck & Co., Inc. Arylheteroaryl inhibitors of farnesyl-protein transferase
JP2000507592A (ja) 1996-04-03 2000-06-20 メルク エンド カンパニー インコーポレーテッド ファルネシル―タンパク質トランスフェラーゼ阻害剤
US5874452A (en) 1996-04-03 1999-02-23 Merck & Co., Inc. Biheteroaryl inhibitors of farnesyl-protein transferase
US5854265A (en) 1996-04-03 1998-12-29 Merck & Co., Inc. Biheteroaryl inhibitors of farnesyl-protein transferase
AU716381B2 (en) 1996-04-03 2000-02-24 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
BR9806989A (pt) 1997-01-24 2000-03-14 Univ California Processo para tratar a epiderme ou membrana da mucosa de um indivìduo mamìfero.
EP1059843A1 (en) 1998-02-25 2000-12-20 Merck & Co., Inc. Method for decreasing qt dispersion or inhibiting the progression of qt dispersion with an angiotensin ii receptor antagonist
EP1115853A2 (en) 1998-09-23 2001-07-18 Ludmila Solomin Analysis of ligand activated nuclear receptors in vivo
WO2000037077A1 (en) 1998-12-23 2000-06-29 Glaxo Group Limited Assays for ligands for nuclear receptors
JP2003506097A (ja) 1999-06-18 2003-02-18 スィーヴィー セラピューティクス インコーポレイテッド Ａｔｐ結合カセット輸送体蛋白質ａｂｃ１を用いるコレステロール流出を増加させｈｄｌを上昇させるための組成物および方法
WO2001082917A2 (en) 2000-05-03 2001-11-08 Tularik Inc. Treatment of hypertriglyceridemia and other conditions using lxr modulators
WO2002000651A2 (en) 2000-06-27 2002-01-03 Bristol-Myers Squibb Pharma Company Factor xa inhibitors
US6924311B2 (en) 2001-10-17 2005-08-02 X-Ceptor Therapeutics, Inc. Methods for affecting various diseases utilizing LXR compounds
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
EP1465869B1 (en) 2001-12-21 2013-05-15 Exelixis Patent Company LLC Modulators of lxr
CA2613517A1 (en) 2005-06-27 2007-01-04 Exelixis, Inc. Pyrazole based lxr modulators
US7741317B2 (en) * 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
AU2007333194A1 (en) * 2006-12-08 2008-06-19 Exelixis, Inc. LXR and FXR modulators
AU2010254082B2 (en) * 2009-05-28 2015-01-29 Exelixis, Inc. LXR modulators
AR088728A1 (es) 2011-03-25 2014-07-02 Bristol Myers Squibb Co Moduladores de lxr como prodroga de imidazol
ES2694001T3 (es) 2013-03-15 2018-12-17 Bristol-Myers Squibb Company Moduladores de LXR

Similar Documents

Publication Publication Date Title
JP2016513730A5 (enExample)
RU2017127135A (ru) Терапевтическое средство против рака желчных протоков
PH12019501131A1 (en) Composition for treating hyperlipidemia comprising oxytomodulin derivative
IL227990B (en) Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl) piperidine-2,6-dione for preparation of medicaments for treatment of immune-related and inflammatory diseases
JP2014507455A5 (enExample)
JP2017537066A5 (enExample)
WO2015018380A3 (en) Therapeutic nanoparticles and the preparation methods thereof
MY159058A (en) Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agent
MX359221B (es) Derivados de tienopiridona útiles como activadores de ampk.
JP2014513110A5 (enExample)
JP2016522835A5 (enExample)
WO2012177481A3 (en) Fibroblast growth factor receptor inhibition for the treatment of disease
WO2016003919A8 (en) Analogs of pridopidine, their preparation and use
MX2010014057A (es) Compuestos de piridina.
JP2016510326A5 (enExample)
JP2016500063A5 (enExample)
JP2015502951A5 (enExample)
RU2018131775A (ru) 6-арил-4-морфолин-1-илпиридоны, пригодные для лечения рака или диабета
JP2015500223A5 (enExample)
CL2012002621A1 (es) Polimorfo forma i, ii, iii, iv y vi de 4-trifluorometil-n-(3,3a,4,4a,5,5a,6,6a-octahidro-1,3-dioxo-4,6-etenocicloprop[f]isoindol-2(1h)-il)-benzamida (st-246); metodo para producirlas; composicion farmaceutica; forma de dosificacion unitaria; y metodo de tratamiento de infecciones por ortopoxvirus y de eczema vacunal.
JP2016518334A5 (enExample)
JP2013525356A5 (enExample)
WO2014192030A3 (en) An improved process for preparation of dabigatran etexilate and pharmaceutically acceptable acid addition salts thereof
CL2013001390A1 (es) 1-[6-(morfolin-4-il)pirimidin-4-il]-4-(1h-1,2,3-triazol-1-il)-1h-pirazol-5-olato sodico; procedimiento de preparacion; composicion farmaceutica y uso en el tratamiento y/o profilaxis de enfermedades tales como insuficiencia cardiaca, anemia, insuficiencia renal y enf. cardiovasculares.
PH12017501830A1 (en) Novel pyridinium compounds